BCAB
BioAtla (BCAB)
$70
About BioAtla (BCAB)
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Details
Daily high
$3.80
Daily low
$3.59
Price at open
$3.59
52 Week High
$71.50
52 Week Low
$3.12
Market cap
6.0M
Dividend yield
0.00%
Volume
26,921
Avg. volume
68,087
P/E ratio
-.09
BioAtla News
Details
Daily high
$3.80
Daily low
$3.59
Price at open
$3.59
52 Week High
$71.50
52 Week Low
$3.12
Market cap
6.0M
Dividend yield
0.00%
Volume
26,921
Avg. volume
68,087
P/E ratio
-.09